Provided by Tiger Trade Technology Pte. Ltd.

Allstate

207.81
+1.640.80%
Post-market: 208.500.6900+0.33%19:42 EDT
Volume:1.42M
Turnover:295.37M
Market Cap:54.05B
PE:5.46
High:210.17
Open:206.99
Low:206.99
Close:206.17
52wk High:216.75
52wk Low:176.00
Shares:260.10M
Float Shares:260.10M
Volume Ratio:1.13
T/O Rate:0.54%
Dividend:4.00
Dividend Rate:1.92%
EPS(TTM):38.06
EPS(LYR):38.06
ROE:39.52%
ROA:6.49%
PB:1.89
PE(LYR):5.46

Loading ...

DC Holdings (00861) Reallocates Funds to Focus on "AI + Supply Chain" Sector

Stock News
·
Dec 09, 2025

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

GlobeNewswire
·
Dec 09, 2025

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

GlobeNewswire
·
Dec 08, 2025

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

GlobeNewswire
·
Dec 08, 2025

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

GlobeNewswire
·
Dec 06, 2025

Allstate (ALL): Reassessing Valuation After Strong Q3 2025 Earnings Beat and Improved Auto Insurance Trends

Simply Wall St.
·
Dec 06, 2025

ALL CONEC Selected for Dream Venture Star 11, Prize Award and MOU Scheduled on November 14

prnewswire
·
Dec 05, 2025

ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL

Stock News
·
Dec 05, 2025

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

GlobeNewswire
·
Dec 05, 2025

Allstate Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Dec 05, 2025

Are Investors Undervaluing Aristocrat Leisure Limited (ASX:ALL) By 24%?

Simply Wall St.
·
Dec 05, 2025

Former Signature Bank executives launch blockchain-based bank

Reuters
·
Dec 04, 2025

Allstate Chairman, President & CEO Thomas J. Wilson Reports Sale of Common Shares

Reuters
·
Dec 04, 2025

Argus Adjusts Price Target on Allstate to $238 From $233, Maintains Buy Rating

MT Newswires Live
·
Dec 03, 2025

Is Allstate’s (ALL) New Scam Protection Benefit Shifting the Digital Security Landscape for Employers?

Simply Wall St.
·
Dec 02, 2025

Suren Gupta, President of Enterprise Solutions, Reports Disposal of Allstate Corporation Common Shares

Reuters
·
Dec 02, 2025

Autonomous Research Adjusts Price Target on Allstate to $202 From $197, Maintains Underperform Rating

MT Newswires Live
·
Dec 01, 2025

Is It Too Late to Consider Allstate After a 12% Surge and Digital Upgrades?

Simply Wall St.
·
Nov 30, 2025

Allstate Is Maintained at Buy by Roth Capital

Dow Jones
·
Nov 26, 2025

Roth Capital Adjusts Price Target on Allstate to $240 From $230, Maintains Buy Rating

MT Newswires Live
·
Nov 26, 2025